Ovarian cancer research (ASCO 2010) Video

Links shared publicly online about this topic.

  • 1,007
    total visits

Ovarian cancer research (ASCO 2010) Video

vodpod.com

Prof Kaye talks about the future of ovarian cancer research. One area that is expected to be very important is research targeting the VEGF protein. A key presentation at ASCO 2010 has shown that a maintenance treatment of avastin, a targeted therapy that blocks VEGF, increases overall survival in ovarian cancer patients. The second area discussed is research into PARP inhibitors. After some spectacular initial results in women with BRCA mutations, a trial presented at ASCO 2010 has shown that ol

View full resource at vodpod.com

Tags: Cancer, Colorectal Cancer Medication, Ovarian Cancer, Protein, Women's Health, Avastin

  • Share

Most Recently Shared on July 21, 2010 at 5:00 am By:

libbyshope Paul Cacciatore

Prof Kaye talks about the future of ovarian cancer research. One area that is expected to be very important is researc… http://bit.ly/bROVq0

2 years ago...

Medical News: ASCO: Avastin Boosts Survival in High-Risk Ovarian Ca - in Meeting Coverage, ASCO from MedPage Today

medpagetoday.com — “CHICAGO -- Adding an anti-angiogenic agent to chemotherapy appears to prolong life in women with high-risk ovarian cancer, a researcher said here.View full resource at medpagetoday.com

  • View Related
  • Share

Most Recently Shared on June 6, 2011 at 1:19 pm By:

MedHealthNews Thomas Loarie, Jr Health Advocate

@medpagetoday ASCO: Avastin Boosts Survival in High-Risk Ovarian Ca (with video) http://bit.ly/j0YUkm #medical #Health

10 months ago...

Key advances in ovarian cancer (ASCO 2010 ) Video

vodpod.com — “Prof Jonathan Ledermann outlines some of the key advances in ovarian cancer that have been presented at ASCO 2010. Prof Ledermann discusses research demonstrating the effectiveness of combining bevacizumab with chemotherapy as first line treatment of ovarian cancer. A second key presentation was research indicating that PARP inhibitors are effective at treating not just ovarian cancer caused by BRCA mutation but also high grade serous cancer. If this result is confirmed in further studies, it woView full resource at vodpod.com

  • View Related
  • Share

Most Recently Shared on July 22, 2010 at 9:59 pm By:

libbyshope Paul Cacciatore Patient Advocate

Prof Jonathan Ledermann outlines some of the key advances in ovarian cancer that have been presented at ASCO 2010. Pro… http://bit.ly/b7acun

2 years ago...

KRAS Gene Variant May Contribute to Ovarian CancerInsidermedicine In 60 - July 20, 2010 Video

vodpod.com — “Scientists have identified a genetic marker that may predict ovarian cancer, according to a report published in Cancer Research. Scientists discovered that 25% of ovarian cancer patients had a variant of the KRAS oncogene compared with only 6% of the general population. As well, this variant was found in 61% of patients who also had a family history of breast and ovarian cancer. 22 Jul 10. From Connecticut - Scientists have identified a genetic marker that may predict ovarian cancer, according tView full resource at vodpod.com

  • View Related
  • Share

Most Recently Shared on July 22, 2010 at 6:45 pm By:

libbyshope Paul Cacciatore Patient Advocate

Scientists have identified a genetic marker that may predict ovarian cancer, according to a report published in Cancer… http://bit.ly/c4hJNo

2 years ago...

Barbara Goff M.D. - Video Chat (2010 OCNA Annual Mtg.) Video

vodpod.com — “Dr. Barbara Goff of the University of Washington, School of Medicine, discusses the latest research in ovarian cancer including an update on screening and early detection. 21 Jul. 10. Dr. Barbara Goff of the University of Washington, School of Medicine, discusses the latest research in ovarian cancer including an update on andView full resource at vodpod.com

  • View Related
  • Share

Most Recently Shared on July 22, 2010 at 4:30 am By:

libbyshope Paul Cacciatore Patient Advocate

Dr. Barbara Goff of the University of Washington, School of Medicine, discusses the latest research in ovarian cancer … http://bit.ly/a2kECw

2 years ago...

Drug developments - PI3K, ERK, BRAF, MEK, mTOR inhibitors (ASCO 2010) Video

vodpod.com — “Dr Silvia Marsoni and Prof Filippo de Braud discuss the key research that has stood out from ASCO 2010, including PI3K, ERK, BRAF, MEK and TOR and inhibitors. Dr Marsoni goes on to explain why it was important that the results presented at this years conference were not exclusively from successful trials, and talks about what we can learn from negative results. Dr Marsoni and Prof de Braud speculate which cancers could be successfully treated with ipilimumab, and discuss the results of a trial iView full resource at vodpod.com

  • View Related
  • Share

Most Recently Shared on July 21, 2010 at 5:16 am By:

libbyshope Paul Cacciatore Patient Advocate

Dr Silvia Marsoni and Prof Filippo de Braud discuss the key research that has stood out from ASCO 2010, including PI3K… http://bit.ly/d6Ih9N

2 years ago...

Dr. Goff Speaks -- Ovarian Cancer National Alliance 2010 Conference - Video

vodpod.com — “Dr. Barbara Goff of the University of Washington, School of Medicine speaks at the 13th Annual Ovarian Cancer National Alliance Conference. Dr. Goff gives the community a research update on screening and early detection in ovarian cancer. 15 Jul 10.View full resource at vodpod.com

  • View Related
  • Share

Most Recently Shared on July 15, 2010 at 11:54 pm By:

libbyshope Paul Cacciatore Patient Advocate

Dr. Barbara Goff of the University of Washington, School of Medicine speaks at the 13th Annual Ovarian Cancer National… http://bit.ly/aZi885

2 years ago...

2010 ASCO: GOG 218, ovarian cancer, and angiogenesis. Video

vodpod.com — “ASCO 2010 Highlights (American Society of Clinical Oncology) Dr. Bradley Monk MD of the University of California Irvine talks about gynecological oncology, GOG 218, ovarian cancer, and angiogenesis. 10 June 10. ASCO 2010 Highlights (American Society of Clinical Oncology) Dr. Bradley Monk MD of the University of California Irvine talks about gynecological oncology, GOG 218, ovarian cancer, and angiogenesis.: ASCO 2010 Highlights (American Society of Clinical Oncology) Dr. Bradley Monk MD of the UView full resource at vodpod.com

  • View Related
  • Share

Most Recently Shared on June 10, 2010 at 8:54 pm By:

libbyshope Paul Cacciatore Patient Advocate

ASCO 2010 Highlights (American Society of Clinical Oncology) Dr. Bradley Monk MD of the University of California Irvin… http://bit.ly/aDX1Bp

2 years ago...

CancerCenter.TV - Super Slogan

cancercenter.tv — “CancerCenter.TV is an emerging educational network that monitors, vets, and redistributes quality web content for community benefit. We intend to support the needs of cancer specialists and the people they serve, through promotion of high quality education, and more effective physician/patient engagement.View full resource at cancercenter.tv

  • View Related
  • Share

Most Recently Shared on June 10, 2010 at 5:03 pm By:

Oncology Videos and Cancer Views from ASCO, ASH, SABCS - ASCO 2010 Highlights (American Society of Clinical Oncology) Dr. Bradley Monk MD of the University of California Irvine talks about gynecological oncology, GOG 218, ovarian cancer, and angiogenesis.

oncologytube.com — “ASCO 2010 Highlights (American Society of Clinical Oncology) Dr. Bradley Monk MD of the University of California Irvine talks about gynecological oncology, GOG 218, ovarian cancer, and angiogenesis.: ASCO 2010 Highlights (American Society of Clinical Oncology) Dr. Bradley Monk MD of the University of California Irvine talks about gynecological oncology, GOG 218, ovarian cancer, and angiogenesis. ...View full resource at oncologytube.com

  • View Related
  • Share

Most Recently Shared on June 9, 2010 at 5:27 pm By:

RMEOncology ReedMedicalEducation Medical Education

Also on #Oncology Congress faculty RT @oncologytube #ASCO10 Highlights Dr Bradley Monk MD of Univ of California I... http://bit.ly/cimyGQ

2 years ago...

ASCO Cancer Drug Treatment Research Highlights Oncology Conference | PBS NewsHour | June 7, 2010 | PBS Video

vodpod.com — “Researchers reported new progress in the treatment of breast, skin, lung and ovarian cancers at a weekend meeting of top cancer experts in Chicago. Ray Suarez talks to American Society of Clinical Oncology President George Sledge for an update on the new medical advances. 08 Jun 10. Researchers reported new progress in the treatment of breast, skin, lung and ovarian cancers at a weekend meeting of top cancer experts in Chicago. Ray Suarez talks to American Society of Clinical Oncology President View full resource at vodpod.com

  • View Related
  • Share

Most Recently Shared on June 8, 2010 at 3:42 pm By:

libbyshope Paul Cacciatore Patient Advocate

Researchers reported new progress in the treatment of breast, skin, lung and ovarian cancers at a weekend meeting of t… http://bit.ly/bB3nVl

2 years ago...

2010 ASCO: GOG-218 Avastin Study Results Video

vodpod.com — “Dr. Jennifer Obel talks about GOG 218 Avastin ovarian cancer study results presented at the 2010 ASCO Annual Meeting. For more information, visit Cancer.Net (http://www.cancer.net). 07 Jun 10. Dr. Jennifer Obel talks about some of the advances in ovarian cancer care coming out of the 2010 ASCO Annual Meeting. For more information, visit Cancer.Net ...View full resource at vodpod.com

  • View Related
  • Share

Most Recently Shared on June 7, 2010 at 5:39 pm By:

libbyshope Paul Cacciatore Patient Advocate

Dr. Jennifer Obel talks about GOG 218 Avastin ovarian cancer study results presented at the 2010 ASCO Annual Meeting. … http://bit.ly/9w1PLC

2 years ago...

2010 ASCO TV: GOG-218 Study of Avastin Video

vodpod.com — “ASCO Daily News presents an exclusive clip from Dr. Robert A. Burger's presentation, "Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study," during yesterday's Plenery Session (LBA1). 07 Jun 10.View full resource at vodpod.com

  • View Related
  • Share

Most Recently Shared on June 7, 2010 at 4:41 pm By:

libbyshope Paul Cacciatore Patient Advocate

ASCO Daily News presents an exclusive clip from Dr. Robert A. Burger's presentation, "Phase III trial of bevacizumab (… http://bit.ly/d9sWPv

2 years ago...

2010 ASCO: Biologic Agent Reduces Ovarian Cancer Relapse Risk - in Meeting Coverage, ASCO from MedPage Today Video

vodpod.com — “Maintenance therapy with a targeted agent significantly reduced the risk of relapse in women with advanced ovarian and related cancers, a researcher said here. Maintenance therapy with bevacizumab (Avastin) after standard chemotherapy decreased the risk of progression by 28% compared with chemo alone, according to Robert Burger, MD, of Fox Chase Cancer Center in Philadelphia. The approach should now be considered "one standard option" for women with advanced epithelial ovarian, primaryView full resource at vodpod.com

  • View Related
  • Share

Most Recently Shared on June 6, 2010 at 10:58 pm By:

libbyshope Paul Cacciatore Patient Advocate

Maintenance therapy with a targeted agent significantly reduced the risk of relapse in women with advanced ovarian and… http://bit.ly/dmsYS9

2 years ago...

2010 Annual Meeting Videos | Cancer.Net

cancer.net — “2010 Annual Meeting Videos | Cancer.Net - The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who treat people with cancer. ASCO's members set the standard for patient care worldwide, and lead the fight for more effective cancer treatments, increased funding for clinical and translational research, and, ultimately, cures for the many different cancers that strike millions of people around the world every year.View full resource at cancer.net

  • View Related
  • Share

Most Recently Shared on June 6, 2010 at 8:27 pm By:

Advertisement